Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine

NCT01906801 ↗

Phase 4 Completed 148 enrolled Ramathibodi Hospital

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare pain scores, WOMAC total and subscores, actual and change of joint space width and the rate of gastrointestinal side effects at 4, 8, 12, and 24 weeks between dual-therapy of diacerein and glucosamine versus a mono-therapy of glucosamine in OA patients

Timeline

Start: 2013-07
Primary completion: 2014-10
Completion: 2014-10

Outcome

Missed primary endpoint

paper The estimated mean difference was 0.09 (95 % CI -0.75 to 0.94), which was not statistically significant (P = 0.710). PMID 27729073 ↗

paper This study did not demonstrate that coadministration of diacerein with pCGS improves pain and WOMAC score PMID 27729073 ↗

Publications

Kongtharvonskul J, Woratanarat P, McEvoy M, Attia J, Wongsak S, Kawinwonggowit V, Thakkinstian A. Efficacy of glucosamine plus diacerein versus monotherapy of glucosamine: a double-blind, parallel randomized clinical trial. Arthritis Res Ther. 2016 Oct 12;18(1):233. doi: 10.1186/s13075-016-1124-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Diacerein	Small molecule	50 mg	Oral
Subject	Glucosamine	Small molecule	1500 mg	Oral